AGN-MAPP is yet another instance of a partnership turning into a buyout. Who will be next?
On top of a large partner adding some level of credibility to what a small-cap biotech is doing, the track record of buyouts in these instances is presumably another reason to look for small-cap biotechs that have legitimate partnerships instead of focusing on those that do not have any drugs in their pipeline partnered or those that otherwise have less well-known partners. (Obviously there are plenty of exceptions to this where small-cap biotechs with no partners eventually land big name partners or get bought out. I'm hoping CLDX becomes one such exception as it's one of my largest holdings now.)
News 
Market Data 
Discover 
